01—Abstract
Summary
Summary of the 8-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth quarter and full year 2023 results in a press release furnished as Exhibit 99.1 to this Item 2.02 filing.
Fourth quarter 2023 total revenue was $230.0 milliona, up 27% year-over-year from $181.5 million, driven by royalty revenue of $122.1 million, higher bulk rHuPH20 sales, XYOSTED growth and higher milestone revenue. Full year 2023 total revenue was $829.3 million, up 26% from $660.1 million, and GAAP diluted EPS was $2.10 versus $1.44 in 2022, while non-GAAP diluted EPS was $2.77 versus $2.21. Full year 2023 net income was $281.6 million and operating income was $337.6 million.
The company reiterated its 2024 guidance, issued January 17, 2024: total revenue of $915 million to $985 millionb, royalty revenue of $500 million to $525 million, adjusted EBITDA of $535 million to $585 million, and non-GAAP diluted EPS of $3.55 to $3.90. Management cited 2023 approvals and positive phase 3 readouts, including VYVGART Hytrulo in CIDP and subcutaneous ocrelizumab and nivolumab, as drivers of future revenue opportunities. Cash, cash equivalents and marketable securities totaled $336.0 million at December 31, 2023, down from $362.8 million a year earlier, mainly due to $400.0 million of share repurchases in 2023.
The filing also discloses a new share repurchase program of up to $750 millionc, announced in February 2024, which follows an accelerated share repurchase agreement entered in November 2023 to complete the remaining $250.0 million of a prior $750 million program. The company's total stockholders' equity fell to $83.8 million at year-end 2023 from $169.8 million, and long-term debt, net, was $1.50 billion.
02—Key points
Key Highlights
- Q4 2023 total revenue of $230.0 million, up 27% year-over-year; Q4 GAAP diluted EPS of $0.65 and non-GAAP diluted EPS of $0.82
- Full year 2023 total revenue of $829.3 million, up 26% from $660.1 million in 2022
- Q4 2023 royalty revenue of $122.1 million, up 15% from $106.0 million a year earlier
- 2024 guidance reiterated: total revenue $915-985 million, adjusted EBITDA $535-585 million, non-GAAP diluted EPS $3.55-3.90
- New share repurchase program of up to $750 million announced in February 2024
- Cash, cash equivalents and marketable securities of $336.0 million at December 31, 2023, versus $362.8 million a year earlier, after $400.0 million of 2023 buybacks
- Partner milestones in 2023 and early 2024 include FDA and EC approvals and a $23.0 million milestone tied to VYVGART SC availability
03—Questions
Frequently Asked Questions
How did Halozyme perform in the fourth quarter and full year 2023?
Fourth quarter 2023 revenue was $230.0 million, up 27% year-over-year, and full year revenue was $829.3 million, up 26%. Full year GAAP diluted EPS was $2.10 and non-GAAP diluted EPS was $2.77.
What guidance did Halozyme give for 2024?
The company reiterated 2024 guidance of total revenue of $915-985 million, royalty revenue of $500-525 million, adjusted EBITDA of $535-585 million and non-GAAP diluted EPS of $3.55-3.90. The EPS guidance does not consider potential future share repurchases.
What is the new share repurchase program?
In February 2024, Halozyme announced a third share repurchase program to buy back up to $750 million of its outstanding common stock. The filing notes that the November 2023 accelerated share repurchase completed the remaining $250.0 million of the prior $750 million program.
What drove the revenue growth?
The filing attributes growth primarily to royalty revenue increases, higher bulk rHuPH20 sales driven by partner demand, continued growth in XYOSTED, and higher milestone revenue. Full year growth also reflected a full year of contributions from the Antares acquisition in May 2022.
How did the balance sheet change during 2023?
Cash, cash equivalents and marketable securities declined to $336.0 million from $362.8 million, mainly due to $400.0 million of share repurchases in 2023. Total stockholders' equity fell to $83.8 million from $169.8 million.
04—Continue